Evidence map›Paper›PMID 25784721›Full record

ArticleMolecular pharmacology2015

Salmeterol Efficacy and Bias in the Activation and Kinase-Mediated Desensitization of β2-Adrenergic Receptors.

Luis E Gimenez, Faiza Baameur, Sharat J Vayttaden, Richard B Clark

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Kinetic analysis of endogenous βBritish journal of pharmacology · 2023
    Article
  4. βBritish journal of pharmacology · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. A cellular perspective of bias at G protein-coupled receptors.Protein science : a publication of the Protein Society · 2020
    Review
  11. Review
  12. Discovery of β-arrestin-biased βActa pharmacologica Sinica · 2019
    Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Luis E GimenezDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (L.E.G.); Division of Internal Medicine, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, Texas (F.B.); and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas (S.J.V., R.B.C.).
Faiza BaameurDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (L.E.G.); Division of Internal Medicine, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, Texas (F.B.); and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas (S.J.V., R.B.C.).
Sharat J VayttadenDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (L.E.G.); Division of Internal Medicine, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, Texas (F.B.); and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas (S.J.V., R.B.C.).
Richard B ClarkDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee (L.E.G.); Division of Internal Medicine, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, Texas (F.B.); and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas (S.J.V., R.B.C.) richard.b.clark@uth.tmc.edu.
The University of Texas MD Anderson Cancer Center · USVanderbilt University Medical Center · US

Funding

Beta Andrenergic Receptor Structure and DesensitizationR01GM031208 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CLARK, RICHARD B · 1985 to 2010
$3.4M
NIGMS NIH HHS GM31208NIGMS NIH HHS R01 GM031208
6 · The paper itself

Abstract

Salmeterol is a long-acting β2-adrenergic receptor (β2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids. Previous studies demonstrated that salmeterol showed weak efficacy for activation of adenylyl cyclase; however, its efficacy in the complex desensitization of the β2AR remains poorly understood. In this work, we provide insights into the roles played by the G protein-coupled receptor kinase/arrestin and protein kinase A in salmeterol-mediated desensitization through bioluminescence resonance energy transfer (BRET) studies of liganded-β2AR binding to arrestin and through kinetic studies of cAMP turnover. First, BRET demonstrated a much reduced efficacy for salmeterol recruitment of arrestin to β2AR relative to isoproterenol. The ratio of BRETISO/BRETSALM after 5-minute stimulation was 20 and decreased to 5 after 35 minutes, reflecting a progressive decline in BRETISO and a stable BRETSALM. Second, to assess salmeterol efficacy for functional desensitization, we examined the kinetics of salmeterol-induced cAMP accumulation (0-30 minutes) in human airway smooth muscle cells in the presence and absence of phosphodiesterase inhibition. Analysis of shaping of cAMP turnover for both agonists demonstrated significant salmeterol desensitization, although it was reduced relative to isoproterenol. Using an isoproterenol rescue protocol after either short-term (10 minutes) or long-term (2 and 14 hours) salmeterol pretreatments, we found that salmeterol progressively depressed isoproterenol stimulation but did not prevent subsequent rescue by isoproterenol and additional isoproterenol-mediated desensitization. Our findings reveal a complex efficacy for functional desensitization, demonstrating that although salmeterol shows weak efficacy for adenylyl cyclase activation and G protein-coupled receptor kinase/arrestin-mediated desensitization, it acts as a strong agonist in highly amplified protein kinase A-mediated events.

Indexed as

3',5'-Cyclic-AMP PhosphodiesterasesAdrenergic beta-AgonistsAlbuterolAnimalsArrestinsbeta-ArrestinsChlorocebus aethiopsCOS CellsCyclic AMPCyclic AMP-Dependent Protein KinasesG-Protein-Coupled Receptor KinasesHumansIsoproterenolMyocytes, Smooth MusclePhosphodiesterase InhibitorsReceptors, Adrenergic, beta-23',5'-Cyclic-AMP PhosphodiesterasesAdrenergic beta-AgonistsAlbuterolArrestinsbeta-ArrestinsCyclic AMPCyclic AMP-Dependent Protein KinasesG-Protein-Coupled Receptor KinasesIsoproterenolPhosphodiesterase InhibitorsReceptors, Adrenergic, beta-2Salmeterol Xinafoate

Identifiers

PMID25784721
PMCPMC4429720
OpenAlexW2049193972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.